Research section Research projects and references

Research: CANCER Folding Project #15302

Project #15302 overview

Project Summary AI Beta

This project explores how a special enzyme called ProcM chooses specific molecules to modify. By using computer simulations, scientists will try to understand how ProcM works at a very detailed level. This knowledge could help us create new drugs and therapies in the future.
Automated summary; simplified and may not be fully accurate.

Project team

Manager(s)
Miko Miwa
Institution
UIUC

Work unit

Atoms
157,982
Core
0x27
Status
Public
Source material

Official Project Description

Lanthipeptides are a class of ribosomally synthesized and post-translationally modified peptides (RiPPs) produced from precursor peptides through dehydration and cyclization reactions.

They exhibit a broad range of bioactivities, including anticancer, antimicrobial, antiviral, and antiallodynic effects.

ProcM, a class II lanthipeptide synthetase, is notable for its high substrate tolerance.

Remarkably, this single enzyme can catalyze the cyclization of a diverse array of substrates with high fidelity—an ability that has been extensively leveraged in the bioengineering of novel lanthipeptides.

Despite this, the molecular mechanism by which ProcM determines the site-selectivity of its substrates remains unclear.

In this study, we aim to perform atomic-level molecular dynamics (MD) simulations of the wild-type (WT) and Variant ProcM–ProcA3.3 complexes to investigate the basis of ProcM's site-selectivity.